Leading Clinical Technology Organization M2S Inc. Announces the Appointment of Jeffrey Yablon as Senior Vice President, Business Development

M2S Inc., a clinical technology organization providing image management services for biopharmaceutical and medical device clinical trials and clinical data registries, announced today that it has named Jeffrey Yablon as its new Senior Vice President, Business Development. In his new role at M2S, Mr. Yablon will be responsible for managing all M2S sales efforts and overseeing the marketing strategy of the rapidly expanding Clinical Trials Imaging, endovascular, and Clinical Data Registries services, in addition to the development and implementation of strategic partnerships.

West Lebanon, NH (PRWEB / PRWEB) April 15, 2009 -- M2S Inc., a clinical technology organization providing image management services for biopharmaceutical and medical device clinical trials and clinical data registries, announced today that it has named Jeffrey Yablon as its new Senior Vice President, Business Development.

Clinical Tech Leader M2S names Jeffrey Yablon SVP Business Development

Mr. Yablon brings over 20 years of experience in the life sciences industry, including senior management roles in pharmaceuticals, drug safety, laboratory management, clinical research, medical imaging and clinical technology. Before joining M2S, Mr. Yablon held the position of Vice President, Sales and Marketing with Sciformix Corporation, a knowledge process outsourcing organization providing pharmacovigilance services to biopharmaceutical and biotech companies. Prior to that position, he held the position of Vice President of Global Business Development at Perceptive Informatics, the technology division of Parexel International. He was also Chief Operating Officer at ICON Laboratories, a division of ICON Plc. Mr. Yablon is a founder of several companies as well as a current instructor and course director at Stony Brook University, Center for Biotechnology in Stony Brook, NY. He began his career at TAP Pharmaceuticals and Abbott Laboratories, where he held various positions of increasing responsibility in sales and marketing. Mr Yablon received his MBA from the executive program at Fairleigh Dickinson University. In his new role at M2S, Mr. Yablon will be responsible for managing all M2S sales efforts and overseeing the marketing strategy of the rapidly expanding Clinical Trials Imaging, Endovascular, and Clinical Data Registries services, in addition to the development and implementation of strategic partnerships.

"Jeffrey has extensive experience and in-depth industry knowledge of the clinical research and informatics industry, and therefore will be a great asset to our organization," said M2S's CEO, Wes Chapman. "He is a well respected and established leader in the clinical trials community, and our clients will greatly benefit from his understanding of their drug and medical device challenges in the new economy. His leadership, combined with the M2S clinical expertise, highly efficient processes and advanced technologies, will continue to advance our market share in the clinical trials and patient data registries markets."

Mr. Yablon says, "I am excited to be part of a truly differentiated Clinical Technology Organization that is able to combine best-in-class technical infrastructure with superior clinical acumen that will directly impact cost, quality, and efficiency to benefit our clients. I look forward to playing a key role in the growth of M2S."

About M2S
M2S is a Clinical Technology Organization (CTO), providing high-quality, timely and cost-effective image data management services for clinical trial sponsors in the biopharmaceutical and medical device industries as well as clinical registry databases. For the past 10 years, M2S has managed, under protocol, over 150 million images from around the globe in all major therapeutic areas and in all DICOM modalities. For more information, visit www.m2s.com

###

See the original story at: http://www.prweb.com/releases/2009/04/prweb2324234.htm

Post Comment:
Trackback URL: http://ca.prweb.com/pingpr.php/WmV0YS1FbXB0LU1hZ24tTWFnbi1QaWdnLUNvdXAtWmVybw==